Equities research analysts expect Endologix, Inc. (NASDAQ:ELGX) to report sales of $35.26 million for the current quarter, Zacks reports. Five analysts have issued estimates for Endologix’s earnings, with estimates ranging from $35.00 million to $35.58 million. Endologix posted sales of $34.76 million during the same quarter last year, which suggests a positive year-over-year growth rate of 1.4%. The company is scheduled to issue its next earnings report on Thursday, November 7th.
On average, analysts expect that Endologix will report full year sales of $142.70 million for the current fiscal year, with estimates ranging from $142.10 million to $143.85 million. For the next year, analysts forecast that the company will post sales of $150.91 million, with estimates ranging from $150.00 million to $152.07 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Endologix.
Endologix (NASDAQ:ELGX) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.43. Endologix had a negative return on equity of 154.23% and a negative net margin of 60.32%. The business had revenue of $36.24 million for the quarter, compared to the consensus estimate of $36.09 million.
ELGX has been the topic of a number of recent analyst reports. Royal Bank of Canada set a $7.00 price objective on Endologix and gave the company a “hold” rating in a report on Friday, August 9th. ValuEngine upgraded Endologix from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded Endologix from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $20.25.
Shares of ELGX traded down $0.30 during mid-day trading on Friday, reaching $6.11. The company’s stock had a trading volume of 244,410 shares, compared to its average volume of 240,310. Endologix has a 12-month low of $5.20 and a 12-month high of $26.50. The firm has a market capitalization of $113.78 million, a PE ratio of -0.85 and a beta of 0.37. The company has a current ratio of 1.58, a quick ratio of 0.90 and a debt-to-equity ratio of 11.12. The firm’s 50 day moving average price is $6.81.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its position in Endologix by 8.9% during the 4th quarter. BlackRock Inc. now owns 6,208,597 shares of the medical instruments supplier’s stock worth $4,446,000 after acquiring an additional 509,493 shares during the period. First Light Asset Management LLC acquired a new stake in Endologix during the 2nd quarter worth approximately $17,828,000. Northern Trust Corp lifted its position in Endologix by 15.9% during the 4th quarter. Northern Trust Corp now owns 1,215,671 shares of the medical instruments supplier’s stock worth $871,000 after acquiring an additional 166,409 shares during the period. Geode Capital Management LLC lifted its position in Endologix by 22.9% during the 4th quarter. Geode Capital Management LLC now owns 1,059,281 shares of the medical instruments supplier’s stock worth $757,000 after acquiring an additional 197,351 shares during the period. Finally, Norges Bank acquired a new stake in Endologix during the 4th quarter worth approximately $545,000. 48.44% of the stock is owned by hedge funds and other institutional investors.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Featured Article: What is the quiet period?
Get a free copy of the Zacks research report on Endologix (ELGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.